{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:31Z","timestamp":1792931971149,"version":"4.5.0"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) remains a formidable therapeutic challenge, with high relapse rates rooted not only in genetic heterogeneity, but also in dynamic and reversible epigenetic dysregulation that drive resistance to conventional and targeted small-molecule therapies. Although small-molecule inhibitors targeting epigenetic regulators have demonstrated preclinical efficacy and initial clinical activity, therapeutic gains are often limited by transient responses, intra- and inter-patient heterogeneity, and an incomplete understanding of predictive biomarkers. Besides, clinical outcomes have often been less robust than preclinical data suggested, partly due to the complexity of AMLs genetic and epigenetic heterogeneity, the limitations of model systems, and intrinsic resistance mechanisms. Combination approaches, such as pairing epigenetic agents with chemotherapy, immunotherapy, or other targeted drugs are under investigation. However, clinical efficacy remains inconsistent and requires a mechanistic rationale to avoid antagonism. To move forward, it is essential to delineate specific epigenetic dependencies in resistance-prone AML subtypes, design rational, biomarker-guided combination regimens, and enhance specificity and pharmacodynamic profiles of epigenetic inhibitors. Such an integrated strategy holds promise for elevating the effectiveness of epigenetic therapies in AML. Continued research is essential to refine epigenetic-based precision medicine and ultimately improve patient outcomes.<\/jats:p>","DOI":"10.3389\/fphar.2025.1672524","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:23:58Z","timestamp":1760937838000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Epigenetic mechanisms of drug resistance in acute myeloid leukemia: advances in small-molecule targeted therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Jialing","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xibo","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zherun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beier","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20406207241306553","DOI":"10.1177\/20406207241306553","article-title":"Mechanisms of resistance to histone deacetylase inhibitors in acute leukemia","volume":"15","author":"Akbarzadeh","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ajh.25929","article-title":"Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia","volume":"95","author":"Aldoss","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"115594","DOI":"10.1016\/j.ejmech.2023.115594","article-title":"Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?","volume":"258","author":"Amin","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12185-018-2563-7","article-title":"Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms","volume":"110","author":"Asada","year":"2019","journal-title":"Int. J. Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"31568","DOI":"10.1038\/s41598-025-17093-z","article-title":"Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation","volume":"15","author":"Atienza Parraga","year":"2025","journal-title":"Sci. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41375-020-1001-z","article-title":"KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements","volume":"35","author":"Au","year":"2021","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","article-title":"Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging","volume":"187","author":"Bandyopadhyay","year":"2024","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2040620718816698","DOI":"10.1177\/2040620718816698","article-title":"Epigenetic therapy combinations in acute myeloid leukemia: what are the options?","volume":"10","author":"Bewersdorf","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clml.2023.09.002","article-title":"Efficacy and safety of immune checkpoint inhibitors in hematologic malignancies","volume":"24","author":"Bilgihan","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"102026","DOI":"10.1016\/j.ctrv.2020.102026","article-title":"ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias","volume":"88","author":"Boudny","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/leu.2016.2","article-title":"BCOR regulates myeloid cell proliferation and differentiation","volume":"30","author":"Cao","year":"2016","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.fertnstert.2021.10.012","article-title":"Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma","volume":"117","author":"Carbajo-Garcia","year":"2022","journal-title":"Fertil. Steril."},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41408-023-00830-w","article-title":"Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics","volume":"13","author":"Carter","year":"2023","journal-title":"Blood Cancer J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1007\/s11864-022-01021-8","article-title":"Pathogenic mechanisms in acute myeloid leukemia","volume":"23","author":"Chakraborty","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/0008-5472.CAN-22-2129","article-title":"SWI\/SNF blockade disrupts PU.1-Directed enhancer programs in normal hematopoietic cells and acute myeloid leukemia","volume":"83","author":"Chambers","year":"2023","journal-title":"Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1158\/1541-7786.MCR-17-0493","article-title":"SMARCB1 deficiency integrates epigenetic signals to oncogenic gene expression program maintenance in human acute myeloid leukemia","volume":"16","author":"Chatterjee","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","article-title":"Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"B154","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","article-title":"Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses","volume":"10","author":"Chen","year":"2020","journal-title":"Acta. Pharm. Sin. B"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41401-025-01479-w","article-title":"Concurrent inhibition of p300\/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia","volume":"46","author":"Chen","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"B21","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 function blocks aberrant self-renewal and leukemia progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41418-023-01139-8","article-title":"Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RAR\u03b1","volume":"30","author":"Dai","year":"2023","journal-title":"Cell Death Differ."},{"key":"B24","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"106197","DOI":"10.1016\/j.leukres.2019.106197","article-title":"Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia","volume":"85","author":"DeAngelo","year":"2019","journal-title":"Leuk. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fonc.2019.00432","article-title":"Intersection of epigenetic and metabolic regulation of histone modifications in acute myeloid leukemia","volume":"9","author":"Dhall","year":"2019","journal-title":"Front. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00432-022-03983-6","article-title":"A phase 1 study of IDH305 in patients with IDH1(R132)-mutant acute myeloid leukemia or myelodysplastic syndrome","volume":"149","author":"DiNardo","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e87448","DOI":"10.1371\/journal.pone.0087448","article-title":"Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5","volume":"9","author":"Dluhosova","year":"2014","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/2159-8290.CD-15-0905","article-title":"Mass cytometry: a high-throughput platform to visualize the heterogeneity of acute myeloid leukemia","volume":"5","author":"Do","year":"2015","journal-title":"Cancer Discov."},{"key":"B33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the european LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1080\/15548627.2020.1822628","article-title":"The role of autophagy in targeted therapy for acute myeloid leukemia","volume":"17","author":"Du","year":"2021","journal-title":"Autophagy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1182\/blood.2023023625","article-title":"Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial","volume":"144","author":"Efficace","year":"2024","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00412-014-0482-9","article-title":"DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance","volume":"123","author":"Esposito","year":"2014","journal-title":"Chromosoma"},{"key":"B151","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/blood.2023022832","article-title":"BRG1\/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor","volume":"143","author":"Fiskus","year":"2024","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"B41","first-page":"373","article-title":"Targeting isocitrate dehydrogenase (IDH) in cancer","volume":"21","author":"Fujii","year":"2016","journal-title":"Discov. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.trecan.2025.01.011","article-title":"Metabolism and therapeutic response in acute myeloid leukemia with IDH1\/2 mutations","volume":"11","author":"Gabellier","year":"2025","journal-title":"Trends Cancer"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/leu.2015.69","article-title":"Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes","volume":"29","author":"Ganan-Gomez","year":"2015","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clml.2021.09.021","article-title":"Oral azacitidine (CC-486) for the treatment of myeloid malignancies","volume":"22","author":"Garcia-Manero","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"","journal-title":"Lancet Haematol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41375-023-02073-x","article-title":"A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML","volume":"38","author":"Garcia-Manero","year":"","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/cpt.2982","article-title":"Population pharmacokinetics of oral azacitidine, and exposure-response analysis in acute myeloid leukemia","volume":"114","author":"Gaudy","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/bjh.19741","article-title":"Oral decitabine\/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: a randomised, crossover, registration, pharmacokinetics study","volume":"205","author":"Geissler","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3390\/microorganisms8081138","article-title":"Biocontrol and plant-growth-promoting traits of Talaromyces apiculatus and Clonostachys rosea consortium against ganoderma basal stem rot disease of oil palm","volume":"8","author":"Goh","year":"2020","journal-title":"Microorganisms"},{"key":"B49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11899-021-00621-9","article-title":"Novel targeted therapeutics in acute myeloid leukemia: an embarrassment of riches","volume":"16","author":"Grieselhuber","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-023-00383-5","article-title":"Synergistic effect of HDAC inhibitor chidamide with cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia","volume":"12","author":"Gu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"8505","DOI":"10.3390\/ijms21228505","article-title":"Deciphering the therapeutic resistance in acute myeloid leukemia","volume":"21","author":"Gurnari","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s0022-5193(88)80060-2","article-title":"Measurement of fractionated water loss and CO2 production using triply labelled water","volume":"134","author":"Haggarty","year":"1988","journal-title":"J. Theor. Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.7150\/thno.53170","article-title":"Tanshinone I, a new EZH2 inhibitor restricts normal and malignant hematopoiesis through upregulation of MMP9 and ABCG2","volume":"11","author":"Huang","year":"2021","journal-title":"Theranostics"},{"key":"B53","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3389\/fonc.2020.00799","article-title":"The KDM inhibitor GSKJ4 triggers CREB downregulation via a protein kinase A and proteasome-dependent mechanism in human acute myeloid leukemia cells","volume":"10","author":"Illiano","year":"2020","journal-title":"Front. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"B147","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.clml.2013.05.004","article-title":"Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin. Lymphoma. Myeloma. Leuk."},{"key":"B55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.exphem.2019.07.002","article-title":"Transcription factor Oct1 protects against hematopoietic stress and promotes acute myeloid leukemia","volume":"76","author":"Jafek","year":"2019","journal-title":"Exp. Hematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13046-022-02248-x","article-title":"SMARCA5 interacts with NUP98-NSD1 oncofusion protein and sustains hematopoietic cells transformation","volume":"41","author":"Jevtic","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"12416","DOI":"10.1073\/pnas.1811040116","article-title":"Dual mechanisms of posttranscriptional regulation of Tet2 by Let-7 microRNA in macrophages","volume":"116","author":"Jiang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: treatment and research outlook for 2021 and the MD anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5483\/bmbrep.2015.48.5.021","article-title":"Isocitrate dehydrogenase mutations: new opportunities for translational research","volume":"48","author":"Keum","year":"2015","journal-title":"BMB Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/1541-7786.MCR-12-0332","article-title":"Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer","volume":"11","author":"Kim","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-022-01339-8","article-title":"Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation","volume":"15","author":"Kunadt","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1080\/10428194.2019.1602260","article-title":"Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications","volume":"60","author":"Lee","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.3346\/jkms.2021.36.e85","article-title":"Recent clinical update of acute myeloid leukemia: focus on epigenetic therapies","volume":"36","author":"Lee","year":"2021","journal-title":"J. Korean Med. Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/bib\/bbx007","article-title":"Genome-wide characterization of lncRNAs in acute myeloid leukemia","volume":"19","author":"Lei","year":"2018","journal-title":"Brief. Bioinform"},{"key":"B65","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1080\/15384101.2020.1750814","article-title":"Long non-coding RNA UCA1 modulates cell proliferation and apoptosis by regulating miR-296-3p\/Myc axis in acute myeloid leukemia","volume":"19","author":"Li","year":"2020","journal-title":"Cell Cycle"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.stem.2023.07.001","article-title":"TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal","volume":"30","author":"Li","year":"2023","journal-title":"Cell Stem Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41375-022-01755-2","article-title":"Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia","volume":"37","author":"Ling","year":"2023","journal-title":"Leukemia"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e98270","DOI":"10.1371\/journal.pone.0098270","article-title":"DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"B71","doi-asserted-by":"publisher","first-page":"109605","DOI":"10.1016\/j.intimp.2022.109605","article-title":"Hepatocyte-derived exosomes deliver H2AFJ to hepatic stellate cells and promote liver fibrosis via the MAPK\/STMN1 axis activation","volume":"115","author":"Liu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-024-00479-6","article-title":"Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance","volume":"13","author":"Liu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ajh.26892","article-title":"Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia","volume":"98","author":"Lo","year":"2023","journal-title":"Am. J. Hematol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.leukres.2007.10.001","article-title":"Genomic variation at the MDR1 promoter and P-glycoprotein expression and activity in AML patients","volume":"32","author":"Lourenco","year":"2008","journal-title":"Leuk. Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/leu.2009.182","article-title":"The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair","volume":"23","author":"Maiso","year":"2009","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1549792","DOI":"10.3389\/fonc.2025.1549792","article-title":"Lysosome targeted therapies in hematological malignancies","volume":"15","author":"Manivannan","year":"2025","journal-title":"Front. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-3-319-53156-4_4","article-title":"Harnessing the immune system against leukemia: monoclonal antibodies and checkpoint strategies for AML","volume":"995","author":"Masarova","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-021-03738-0","article-title":"A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival","volume":"12","author":"Massett","year":"2021","journal-title":"Cell Death Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","article-title":"IDH inhibitors in AML-promise and pitfalls","volume":"16","author":"McMurry","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B80","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/leu.2012.342","article-title":"Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia","volume":"27","author":"Mims","year":"2013","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3324\/haematol.2017.186890","article-title":"A novel regimen for relapsed\/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485","volume":"103","author":"Mims","year":"2018","journal-title":"Haematologica"},{"key":"B82","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/ijms25010484","article-title":"Venetoclax and hypomethylating agent combination in myeloid malignancies: mechanisms of synergy and challenges of resistance","volume":"25","author":"Mishra","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022018092","article-title":"Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets","volume":"141","author":"Mishra","year":"","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-Mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.3390\/ijms21082907","article-title":"The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells","volume":"21","author":"Nepstad","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/leu.2011.159","article-title":"p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia","volume":"25","author":"Ng","year":"2011","journal-title":"Leukemia"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e93019","DOI":"10.7554\/eLife.93019","article-title":"Convergent epigenetic evolution drives relapse in acute myeloid leukemia","volume":"13","author":"Nuno","year":"2024","journal-title":"Elife"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/cancers11101424","article-title":"DNA methylation of enhancer elements in myeloid neoplasms: think outside the promoters?","volume":"11","author":"Ordonez","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"444","DOI":"10.14348\/molcells.2018.2311","article-title":"AURKA suppresses leukemic THP-1 cell differentiation through inhibition of the KDM6B pathway","volume":"41","author":"Park","year":"2018","journal-title":"Mol. Cells"},{"key":"B90","first-page":"38","article-title":"Acute myeloid leukemia: a review","volume":"103","author":"Pelcovits","year":"2020","journal-title":"R. I. Med. J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e2022080","DOI":"10.4084\/MJHID.2022.080","article-title":"The growing role of the BH3 mimetic drug venetoclax in the therapy of acute myeloid leukemia","volume":"14","author":"Pelosi","year":"2022","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"B150","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12885-024-12286-7","article-title":"Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK\/H2AX\/Mcl-1 axis","volume":"24","author":"Qiu","year":"2024","journal-title":"BMC Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","article-title":"Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells","volume":"78","author":"Rahmani","year":"2018","journal-title":"Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-20-1346","article-title":"BET inhibition enhances the antileukemic activity of low-dose venetoclax in acute myeloid leukemia","volume":"27","author":"Ramsey","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/bjh.19202","article-title":"Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001","volume":"204","author":"Ravandi","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15592294.2017.1413517","article-title":"Low HOX gene expression in PML-RAR\u03b1-positive leukemia results from suppressed histone demethylation","volume":"13","author":"Rejlova","year":"2018","journal-title":"Epigenetics"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1080\/10428194.2021.1881509","article-title":"A dose escalation study of RO6870810\/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"62","author":"Roboz","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"B156","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","article-title":"The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers","volume":"25","author":"Russler-Germain","year":"2014","journal-title":"Cancer Cell"},{"key":"B98","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","article-title":"CAR-T cell therapy in AML: recent progress and future perspectives","volume":"120","author":"Saito","year":"2024","journal-title":"Int. J. Hematol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/cancers11111794","article-title":"HDAC inhibitors in acute myeloid leukemia","volume":"11","author":"San Jose-Eneriz","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"141","DOI":"10.14218\/JCTH.2018.00002","article-title":"Effect of genistein in comparison with trichostatin A on reactivation of DNMTs genes in hepatocellular carcinoma","volume":"6","author":"Sanaei","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1182\/blood-2015-07-655928","article-title":"Increased DNA methylation of Dnmt3b targets impairs leukemogenesis","volume":"127","author":"Schulze","year":"2016","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1186\/s12885-017-3803-6","article-title":"Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens","volume":"17","author":"Seymour","year":"2017","journal-title":"BMC Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.exphem.2022.03.008","article-title":"Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations","volume":"110","author":"Shabashvili","year":"2022","journal-title":"Exp. Hematol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.blre.2016.02.001","article-title":"Update on rational targeted therapy in AML","volume":"30","author":"Shafer","year":"2016","journal-title":"Blood Rev."},{"key":"B107","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood.2022019306","article-title":"Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation","volume":"145","author":"Shah","year":"2025","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"B109","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.exphem.2018.10.011","article-title":"CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p\/miR-183-5p-XIAP axis","volume":"70","author":"Shang","year":"2019","journal-title":"Exp. Hematol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2017-05-787226","article-title":"Ring1A and Ring1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells","volume":"131","author":"Shima","year":"2018","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","article-title":"Modulation of cellular processes by histone and non-histone protein acetylation","volume":"23","author":"Shvedunova","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/sj.onc.1208431","article-title":"Constitutive activation of the wnt\/beta-catenin signalling pathway in acute myeloid leukaemia","volume":"24","author":"Simon","year":"2005","journal-title":"Oncogene"},{"key":"B113","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/cncr.31837","article-title":"Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery","volume":"125","author":"Simonetti","year":"2019","journal-title":"Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"L012101","DOI":"10.1103\/PhysRevE.104.L012101","article-title":"Spontaneous dimensional reduction and ground state degeneracy in a simple chain model","volume":"104","author":"Skrbic","year":"2021","journal-title":"Phys. Rev. E"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"B117","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/bloodadvances.2020003709","article-title":"Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets","volume":"5","author":"Stratmann","year":"2021","journal-title":"Blood Adv."},{"key":"B118","doi-asserted-by":"publisher","first-page":"e65905","DOI":"10.7554\/eLife.65905","article-title":"Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia","volume":"10","author":"Takao","year":"2021","journal-title":"Elife"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2147\/OTT.S384293","article-title":"Therapeutic targeting of FLT3 in acute myeloid leukemia: current status and novel approaches","volume":"15","author":"Tecik","year":"2022","journal-title":"Onco Targets Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"604391","DOI":"10.3389\/fcell.2020.604391","article-title":"Real-time molecular monitoring in acute myeloid leukemia with circulating tumor DNA","volume":"8","author":"Thakral","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/2159-8290.CD-21-0218","article-title":"Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability","volume":"13","author":"Thomas","year":"2023","journal-title":"Cancer Discov."},{"key":"B122","doi-asserted-by":"publisher","first-page":"982424","DOI":"10.3389\/fphar.2022.982424","article-title":"Recent advances of IDH1 mutant inhibitor in cancer therapy","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"116447","DOI":"10.1016\/j.ejmech.2024.116447","article-title":"Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine","volume":"272","author":"Tretbar","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.apsb.2021.10.025","article-title":"PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia","volume":"12","author":"Tsai","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"B125","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/cancers5030857","article-title":"Induction of chromosomal instability via telomere dysfunction and epigenetic alterations in myeloid neoplasia","volume":"5","author":"Vajen","year":"2013","journal-title":"Cancers (Basel)"},{"key":"B148","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/16078454.2021.1921434","article-title":"Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia","volume":"26","author":"Wang","year":"2021","journal-title":"Hematology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood.2024026916","article-title":"Sequential epigenetic therapy in AML","volume":"145","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13148-020-00923-4","article-title":"Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed\/refractory acute myeloid leukemia: a single-arm, phase 1\/2 study","volume":"12","author":"Wang","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","first-page":"217290","DOI":"10.1016\/j.canlet.2024.217290","article-title":"Inhibition of TGF-beta signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"B130","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41375-020-0892-z","article-title":"A proof of concept phase I\/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory\/relapsed AML patients not eligible for intensive therapy","volume":"35","author":"Wass","year":"2021","journal-title":"Leukemia"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2017.10.015","article-title":"Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo","volume":"413","author":"Wen","year":"2018","journal-title":"Cancer Lett."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1177271919846454","DOI":"10.1177\/1177271919846454","article-title":"Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid leukaemia","volume":"14","author":"Wong","year":"2019","journal-title":"Biomark. Insights"},{"key":"B134","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","article-title":"Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia","volume":"127","author":"Wouters","year":"2016","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"975819","DOI":"10.3389\/fped.2022.975819","article-title":"Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia","volume":"10","author":"Xu","year":"2022","journal-title":"Front. Pediatr."},{"key":"B136","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/1541-7786.MCR-13-0596","article-title":"Clarifying the impact of polycomb complex component disruption in human cancers","volume":"12","author":"Yamamoto","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"e2100914","DOI":"10.1002\/advs.202100914","article-title":"Cytoplasmic NEAT1 suppresses AML stem cell self-renewal and leukemogenesis through inactivation of wnt signaling","volume":"8","author":"Yan","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"key":"B138","doi-asserted-by":"publisher","first-page":"117521","DOI":"10.1016\/j.ejmech.2025.117521","article-title":"Design, synthesis and biological evaluation of 3-amino-6-(2-hydroxyphenyl)pyridazin-4-aryl derivatives as SMARCA2\/4 degraders","volume":"290","author":"Yang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02657-9","article-title":"The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia","author":"Yu","year":"2025","journal-title":"Leukemia"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/bloodadvances.2023011858","article-title":"Dual-targeting CD33\/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile","volume":"8","author":"Zeng","year":"2024","journal-title":"Blood Adv."},{"key":"B141","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1039\/d2an01114j","article-title":"A dynamic fluorescence probed glycolysis suppression process in HeLa cells treated with trichostatin A","volume":"147","author":"Zhang","year":"2022","journal-title":"Analyst"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3892\/ijo.2020.5033","article-title":"Clinical efficacy of decitabine-containing induction chemotherapy in de novo non-elderly acute myeloid leukemia","volume":"56","author":"Zheng","year":"2020","journal-title":"Int. J. Oncol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3892\/ijo.2023.5588","article-title":"MEK\/ERK and PI3K\/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de-methylases","volume":"63","author":"Zheng","year":"2023","journal-title":"Int. J. Oncol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41422-024-00947-y","article-title":"Editorial expression of concern: HDAC2 phosphorylation-dependent Klf5 deacetylation and RAR\u03b1 acetylation induced by RAR agonist switch the transcription regulatory programs of p21 in VSMCs","volume":"34","author":"Zheng","year":"2024","journal-title":"Cell Res."},{"key":"B145","doi-asserted-by":"publisher","first-page":"eadi1782","DOI":"10.1126\/sciadv.adi1782","article-title":"RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-Mutated AML cells","volume":"10","author":"Zhu","year":"2024","journal-title":"Sci. Adv."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1672524\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T13:09:43Z","timestamp":1761138583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1672524\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":154,"alternative-id":["10.3389\/fphar.2025.1672524"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1672524","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1672524"}}